Physician profile
Adam D Mark
NPI 1275537961
$2,563.80
in general payments reported to CMS, 2019-2025
14 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $304 · 2021: $237 · 2022: $584 · 2023: $277 · 2024: $231 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,037.16 | 2019-2023 | Myday Contact Lens |
| Alcon Vision LLC | $497.78 | 2019-2025 | Precision7, Total30, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $176.73 | 2020-2023 | Acuvue |
| Visioneering Technologies, INC. | $168.06 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $161.82 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $146.27 | 2022-2025 | Infuse |
| Maculogix, INC. | $114.38 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $74.91 | 2019-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.72 | 2019-2021 | |
| Genzyme Corporation | $43.88 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.13 | 2020-2022 | |
| Lkc Technologies, INC. | $17.09 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $16.94 | 2020 | |
| Kala Pharmaceuticals, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.